{"id":"W4417011029","doi":"10.1182/blood-2025-269","title":"Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Multiple myeloma; Clinical trial; Adverse effect; Phases of clinical research; Lenalidomide; Progressive disease; Safety profile","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001217601,0.0006185931,0.0009347742,0.000219053,0.0002879078,0.0007993429,0.0005627426,0.0006383045,0.001781218],"category_scores_gemma":[0.0006719733,0.000206593,0.0007501456,0.0002942235,0.0004910912,0.0004478773,0.0002433848,0.002004489,0.0004576827],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001016144,"about_ca_system_score_gemma":0.0009864945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001284973,"about_ca_topic_score_gemma":0.003300908,"domain_scores_codex":[0.9995981,0.0001908981,0.00002857981,0.00006375464,0.00005752615,0.00006107914],"domain_scores_gemma":[0.9996045,0.00007577961,0.000105927,0.00003569352,0.00003699076,0.0001411219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3583063,0.03590202,0.02342927,0.001547783,0.002388375,0.0004893664,0.0004730033,0.005083478,0.2148106,0.0005327596,0.01260577,0.3444312],"study_design_scores_gemma":[0.1621651,0.6779287,0.07416971,0.0001331578,0.002901472,0.001839816,0.0002235125,0.006927059,0.05239501,0.0007825252,0.02043369,0.0001001826],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899031,0.005217283,0.000665449,0.000433037,0.0000664168,0.0003712888,0.001329379,0.0001138318,0.001900079],"genre_scores_gemma":[0.9951614,0.001192833,0.0005493478,0.0003929278,0.00004792161,0.0001729685,0.001634365,0.00001834235,0.0008299652],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001781218,"threshold_uncertainty_score":0.007372618,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02062231640243224,"score_gpt":0.3042029586185255,"score_spread":0.2835806422160933,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}